NFGH
PRLD icon

Nan Fung Group Holdings’s Prelude Therapeutics PRLD Stock Holding History

Nan Fung Group Holdings’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-20,350
Closed -$253K – 53
2021
Q4 		$253K Buy
+20,350
New +$331K 0.07% 42

Other funds holding PRLD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Nan Fung Group Holdings's PRLD Position: Q1 2022 in Review

Nan Fung Group Holdings sold out of Prelude Therapeutics (PRLD) in Q1 2022, closing a stake of 20,350 shares — an estimated $253K sold.

Nan Fung Group Holdings first reported a position in PRLD in Q4 2021 and held it in 1 quarter. The position peaked at $253K in Q4 2021. 68 funds tracked by Wall St. Rank hold PRLD as of Q1 2022.

  • Nan Fung Group Holdings reported no remaining Prelude Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Nan Fung Group Holdings sold 20,350 Prelude Therapeutics shares in Q1 2022, an estimated $253K.
  • Nan Fung Group Holdings first reported a position in Prelude Therapeutics in Q4 2021 and held it in 1 quarter.
  • Nan Fung Group Holdings's Prelude Therapeutics position peaked at $253K in Q4 2021.
  • 68 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q1 2022.

Based on Nan Fung Group Holdings's 13F filing for Q1 2022, filed 13 May 2022.